遵循特发性多中心Castleman病指南的治疗与结局改善相关
基于ACCELERATE自然史登记研究,对102例专家确认的特发性多中心Castleman病(iMCD)患者分析治疗方案与应答,发现司妥昔单抗联合或不联合糖皮质激素应答率52%,单用糖皮质激素3%,细胞毒化疗52%主要用于TAFRO特征患者,结果支持现行指南一线使用抗IL6治疗。
要点
- 司妥昔单抗联合或不联合糖皮质激素的应答率为52%,单用糖皮质激素为3%。
- 抗IL6治疗(司妥昔单抗或托珠单抗)应答和持久性优于利妥昔单抗联合或不联合糖皮质激素。
- 细胞毒化疗应答率52%,主要用于伴血小板减少、全身水肿、发热、肾功能衰竭/网状纤维化及器官肿大的患者。
核心结论
- 结果支持现行推荐:一线使用抗IL6治疗,严重难治性疾病使用细胞毒化疗,并限制单用糖皮质激素。
- 对anti-IL6-directed therapy难治患者的有效药物证据仍然有限。
研究设计与样本
- 基于ACCELERATE Natural History Registry,纳入102例专家确认的iMCD病例,盘点治疗方案并评估方案应答。
- 该试验注册于www.clinicaltrials.gov,注册号为#NCT02817997。
主要发现
- 司妥昔单抗联合或不联合糖皮质激素与52%的应答相关,而单用糖皮质激素与3%的应答相关。
- 抗IL6治疗(司妥昔单抗或托珠单抗)的应答和持久性优于利妥昔单抗联合或不联合糖皮质激素。
- 细胞毒化疗与52%的应答相关,主要用于以血小板减少、全身水肿、发热、肾功能衰竭/网状纤维化及器官肿大为特征的患者。
关键数值与推荐
- 2018年制定的国际共识治疗指南推荐司妥昔单抗一线治疗,托珠单抗在司妥昔单抗不可及时推荐。
- 化疗、利妥昔单抗和免疫调节剂基于有限证据推荐为二线和三线治疗。
- 单用糖皮质激素不被推荐,但临床医生仍在使用。
临床怎么用
- 现行指南推荐一线使用抗IL6治疗。
- 现行指南推荐严重难治性疾病患者使用细胞毒化疗。
- 现行指南推荐限制单用糖皮质激素。
局限性
- 2018年国际共识治疗指南依赖于数量有限的临床试验和小型病例系列。
- 据作者所知,这些推荐的real-world performance此后尚未被研究。
- 对anti-IL6-directed therapy难治患者的有效药物证据仍然有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic multicentric Castleman disease (iMCD) is a rare hematologic disorder with an unknown etiology. Clinical presentation is heterogeneous, ranging from mild constitutional symptoms with lymphadenopathy to life-threatening multiorgan dysfunction. International, consensus treatment guidelines developed in 2018 relied upon a limited number of clinical trials and small case series; however, to our knowledge, real-world performance of these recommendations has not been subsequently studied. Siltuximab, a monoclonal antibody against interleukin 6 (IL6), is approved for the treatment of iMCD and recommended first-line, and tocilizumab, a monoclonal antibody directed against the IL6 receptor, is recommended when siltuximab is unavailable. Chemotherapy, rituximab, and immunomodulators are recommended as second- and third-line treatments based on limited evidence. Corticosteroid monotherapy is used by clinicians, although not recommended. Here, we draw upon the ACCELERATE Natural History Registry to inventory regimens and evaluate regimen response for 102 expert-confirmed iMCD cases. Siltuximab with/without (w/wo) corticosteroids was associated with a 52% response, whereas corticosteroid monotherapy was associated with a 3% response. Anti-IL6-directed therapy with siltuximab or tocilizumab demonstrated better response and more durability than was observed with rituximab w/wo corticosteroids. Cytotoxic chemotherapy was associated with a 52% response and was predominantly administered in patients characterized by thrombocytopenia, anasarca, fever, renal failure/reticulin fibrosis, and organomegaly. Our results provide evidence in support of current recommendations to administer anti-IL6 as first-line treatment, to administer cytotoxic chemotherapy in patients with severe refractory disease, and to limit corticosteroid monotherapy. Evidence remains limited for effective agents for patients who are refractory to anti-IL6-directed therapy. This trial was registered at www.clinicaltrials.gov as #NCT02817997.
引用
- Pierson SK, Lim MS, Srkalovic G, et al. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes. Blood Adv. 2023. PMID: 37656441. doi:10.1182/bloodadvances.2023010745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。